|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Apricus Biosciences (APRI) Announces That Its NexACT(R) Partner Exodos Life Sciences Has Completed Its pre-IND Meeting With the FDA
11/15/2011 9:26:08 AM
SAN DIEGO, Nov. 15, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) announced today that its NexACT® out-licensing partner, Exodos Life Science Limited Partnership ("Exodos"), a privately-held company located in Chapel Hill, North Carolina, has completed a successful pre-IND ("Investigational New Drug Application") meeting with the U.S. Food and Drug Administration ("FDA") regarding its plan to conduct clinical trials to establish the safety and effectiveness of its patented, topical painkilling drug, ELS115, containing NexACT® technology licensed from Apricus Bio.
|
|
|
|
|
|
|
|
|
|
|